KOL believes elsbasvir and grazoprevir data will lead to approval and look similar to available drugs on the market (MRK).
Post-liver transplant data for sofosbuvir and simpeprevir was positive (GLD, JNJ).
Three DAA combination of -5816,-9857, and sofosbuvir looked good, but most physicians are erring on the side of conservative 12- week treatment regimens except in patients with very low viral loads and little fibrosis (GLD).
Daclatasvir in combination with Sovaldi will be effective in GT3 patients with or without ribavirin (GLD, BMY).
KOL treats 85% of patients with Harvoni or sovaldi plus Olysio, and he treats about 15% of patients with Viekira Pak primarily for insurance reasons. He avoids the use of ribavirin if at all possible (BMY, JNJ, ABBV).
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.